Hormonal Heterogeneity of Endometrial Cancer

Gründker, Carsten; Günthert, Andreas R.; Emons, Günter

doi:10.1007/978-0-387-78818-0_11

Cited by 23 publications

(19 citation statements)

References 220 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Frequently the advanced carcinomas are temporally and spatially associated with endometrial hyperplasia [14][15][16] . To test our hypothesis that changes in PTEN structure and function are among the earliest events in the pathway to endometrial cancer and precancer, we measured the expression of PTEN in endometrial hyperplasia and found that the differences were very significant between endometrial atypical hyperplasia and the three subtypes of endometrial hyperplasia, but there was no significant difference among the three subgroups of endometrial hyperplasia.…”

Section: Expression Of Pten In Endometrial Carcinomamentioning

confidence: 99%

Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma

Gao

Xia

et al. 2009

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

In order to investigate the role of the PTEN expression in carcinogenesis and development of endometrial carcinoma and clarify whether and how PTEN and PI3K/Akt pathway relate to endometrial carcinoma, the expression of PTEN and phospho-Akt was detected by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) methods and Western-blot from 24 cases of endometrial carcinoma, 10 cases of endometrial atypical hyperplasia, 10 cases of endometrial hyperplasia, and 10 cases of normal endometrium. SP immunohistochemical methods were used to measure levels of PTEN protein expression in following 5 study groups: 31 cases of endometrium in proliferative phase, 30 cases of endometrium in secretory phase, 71 cases of endometrial hyperplasia, 25 cases of atypical hyperplasia and 73 cases of endometrial carcinoma. Immunostaining score of PTEN was 3.39+/-0.15 in proliferative phase, 1.90+/-0.21 in secretory phase, 3.34+/-0.29 in endometrial hyperplasia, 0.62+/-0.11 in atypical hyperplasia, and 0.74+/-0.19 in endometrial carcinoma, respectively. PTEN mRNA relative value in normal endometrium, endometrial hyperplasia, endometrial atypical hyperplasia, and endometrial carcinoma was 2.45+/-0.51, 2.32+/-0.32, 0.46+/-0.11, and 0.35+/-0.13 respectively. The expression levels of PTEN mRNA and protein in patients with endometrial carcinoma and atypical hyperplasia were significantly lower than in those of proliferative phase and with endometrial hyperplasia. The level of PTEN expression in patients with endometrial carcinoma was significantly related to tissue type (P<0.005), differentiation (P<0.05) and clinical stage (P<0.05), but not to depth of myometrium invasion (P>0.05). Western blot analysis revealed that Phospho-Akt level in PTEN negative cases was significantly higher, and there was a negative correlation between PTEN and phospho-Akt (r=-0.8973, P<0.0001). It was suggested that loss of PTEN expression was an early event in endometrial tumorigenesis. The phosphorylation of Akt induced by the loss of PTEN took part in the tumorigenesis and development of endometrial carcinoma.

show abstract

Section: Expression Of Pten In Endometrial Carcinomamentioning

confidence: 99%

Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma

Gao

Xia

et al. 2009

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

show abstract

“…papillary serous and clear cell) and are sensitive to endocrine treatment (5). The transition from normal endometrium to a malignant tumor is thought to involve a stepwise accumulation of alterations in cellular mechanisms leading to dysfunctional cell growth (6). Type I and type II carcinoma also present different molecular pathways in evolution.…”

Section: Introductionmentioning

confidence: 99%

Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer

et al. 2013

View full text Add to dashboard Cite

Abstract. Endometrial cancer is a common gynecological malignancy with a good prognosis in early stages of the disease. The CpG island in the promoter region of tumorsuppressor genes are frequently methylated in various types of human cancers. In the present study, we examined the methylation status of the GSTP1, CDH1 and RASSF1A genes in endometrioid endometrial cancer (EEC), endometrial complex hyperplasia (EHP) and healthy endometrium with the aim to identify correlations between promoter hypermethylation, disease risk and clinicopathological parameters. A nested two-stage methylation-specific PCR (MSP) was performed to analyze the promoter CpG methylation status of GSTP1, CDH1 and RASSF1A genes in the population studied. A total of 92 subjects were initially included in the study of which 41 EEC, 19 EHP and 20 controls were processed for final analyses. A significant difference was found between the study groups and the presence of promoter CpG hypermethylation status in the GSTP1 (P<0.05) and RASSF1A (P<0.0001) genes. RASSF1A, GSTP1 and CDH1 gene promoter methylation was present in 85.4, 68.3 and 31.4% of EEC samples when compared to that in the controls with 30.0, 35.0 and 20.0%, respectively. CpG methylation of all three investigated tumor-suppressor genes was found in 12.2% of EEC patients, in 4.2% of EHP patients and in 3.7% of the controls, respectively. Positive findings for the promoter methylation of two investigated genes were found in 48.7% of EEC patients, 26.0% of EHP patients and in 18.5% of the controls. With regard to histopathological variables and CpG methylation, we found significant correlations between the RASSF1A and GSTP1 genes and higher tumor grade, deeper myometrial invasion and positive metastatic involvement of pelvic lymph nodes. No associations were noted between promoter hypermethylation of the CDH1 gene and biological features of the endometrial cancer cases. The results indicate that aberrant CpG methylation of the promoter region in the GSTP1 and RASSF1A tumor-suppressor genes is an important event in carcinogenesis of endometrial cancer and may have an impact on tumor aggressiveness. Finally, the present study suggests that epigenetic alterations may be of diagnostic value for the better clinical management of premalignant endometrial lesions.

show abstract

“…Prognosis of UPSC is affected by age, stage, and histology as well as treatment (105) . The KLK6 gene is differentially expressed in UPSC, in comparison with other subtypes of endometrial carcinoma and/or healthy tissue (96) .…”

Section: Uterine Papillary Serous Carcinomamentioning

confidence: 99%

Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers

Kontos

Scorilas

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Early diagnosis of cancer and early detection of relapse following surgery are critical for the effective treatment of the disease and for a positive clinical outcome. Identifi cation of novel diagnostic, prognostic and predictive biomarkers will contribute utmost to clinical decision-making. The human tissue kallikrein and kallikrein-related peptidases (KLKs), encoded by the largest contiguous cluster of protease genes in the human genome, are secreted serine proteases with diverse expression patterns and physiological roles. The aberrant expression of KLK s in various malignancies as well as their involvement in many cancer-related processes, such as cell growth regulation, angiogenesis, invasion, and metastasis, has prompted scientists to investigate their potential as cancer biomarkers. Expression of distinct KLKs is associated with clinicopathological parameters of cancer patients. Moreover, several KLKs possess signifi cant favorable or unfavorable prognostic value in various malignancies, with prostate-specifi c antigen (PSA) being the most widely used biomarker in clinical practice, today. KLKs are also considered as very promising biomarkers for cancer personalized medicine, especially for prediction and monitoring of patients ' response to chemotherapy, therefore opening up new horizons towards effective patient monitoring post-treatment. This review describes the current status of KLKs as tumor biomarkers.

show abstract

Hormonal Heterogeneity of Endometrial Cancer

Cited by 23 publications

References 220 publications

Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma

Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma

Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer

Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers

Contact Info

Product

Resources

About